Clinical Trial Update: A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study of ocrelizumab in adults with moderate to severe rheumatoid arthritis was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: TERMINATED